Scholarlink

<p>While antiseizure medications (ASMs) exhibit the ability to influence the immune system, the specific immunosuppressive consequences in neonates remain insufficiently delineated. Levetiracetam is regarded a safe and effective second-line treatment following phenobarbital, particularly in cases where first-line agents are ineffective or result in adverse reactions in neonatal seizures. We present a neonate who developed B-cell lymphopenia due to levetiracetam administration, which constitutes a previously unrecognized adverse effect of the medication in neonates. To our knowledge, this case marks the initial documented occurrence of B-cell lymphopenia associated with levetiracetam in a neonate.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Levetiracetam- associated B-cell lymphopenia in a neonate: a rare case report

  • 期刊论文

  • 发表日期：

    2026年5月1日

查看全文
  • Muhammed Ibrahim Ozsuer,
  • Ilknur Kulhas Celik,
  • Murat Konak,
  • Hasibe Artac

摘要

While antiseizure medications (ASMs) exhibit the ability to influence the immune system, the specific immunosuppressive consequences in neonates remain insufficiently delineated. Levetiracetam is regarded a safe and effective second-line treatment following phenobarbital, particularly in cases where first-line agents are ineffective or result in adverse reactions in neonatal seizures. We present a neonate who developed B-cell lymphopenia due to levetiracetam administration, which constitutes a previously unrecognized adverse effect of the medication in neonates. To our knowledge, this case marks the initial documented occurrence of B-cell lymphopenia associated with levetiracetam in a neonate.